Literature DB >> 29675341

Challenging issues in ocular adnexal disorders.

Chieh-Chih Tsai1,2.   

Abstract

Entities:  

Year:  2018        PMID: 29675341      PMCID: PMC5890577          DOI: 10.4103/2211-5056.226470

Source DB:  PubMed          Journal:  Taiwan J Ophthalmol        ISSN: 2211-5056


× No keyword cloud information.
Ocular adnexa includes a wide variety of anatomical structures including the eyelids, conjunctiva, carunculae, lacrimal gland, lacrimal drainage system, extraocular muscles, and soft tissues, and it is surrounded by seven bones. These complex and highly specialized tissues result in a large spectrum of inflammatory, benign, and malignant disorders. In this issue, we selected several challenging topics about the diagnosis and management of ocular adnexal disorders.

Unilateral Congenital Ptosis

Patients with unilateral congenital ptosis are more predisposed to developing amblyopia, usually due to strabismus, high astigmatism, or anisometropia.[123] Unilateral severe congenital ptosis remains a major challenge for the oculoplastic surgeon because there is still much debate about which one is the optimal method. Common surgical procedures include unilateral frontalis suspension with autogenous or exogenous materials, maximal levator resection, or bilateral frontalis suspension with or without levator muscle excision of the normal eyelid. To reduce the morbidity of donor site or the normal eyelid, and postoperative complications such as undercorrection, lid asymmetry, and poor cosmetic results remain a major concern. Lee and Kim reviewed the literature and introduced the rationale, advantages, and disadvantages of various surgical treatments for unilateral severe congenital ptosis.

Immunoglobulin G4-Related Ophthalmic Disease

Immunoglobulin G4-related disease (IgG4-RD) is increasingly considered to be an emerging fibro-inflammatory condition comprised of a collection of disorders that share particular clinical, pathological, and serological features.[4] IgG4-RD often presents to clinicians with a diagnostic challenge not only for limited understanding but also because of its simultaneous or sequential involvement of multiple organs, including ocular adnexa.[5] Recent evidence supports that part of idiopathic orbital inflammatory syndrome is linked to IgG4-RD and a Japanese prevalence study of IgG4-related ophthalmic disease (IgG4-ROD) showed that approximately a quarter of orbital lymphoproliferative disorders are IgG4-ROD.[6] Yu et al. reviewed and updated the evidence regarding its epidemiology, diagnosis, clinical features, treatment, and the association between lymphoma and IgG4-ROD. The study emphasized the importance of careful clinicoradiologic examination, investigation for other organ involvement, and long-term monitoring for disease relapse or potential neoplastic transformation for patients with IgG4-ROD.

Conjunctival Papilloma

Conjunctival papilloma is an acquired benign epithelial tumor of the conjunctiva with a close causal relationship to human papillomavirus. Despite the multiple choices of therapeutic modalities for treating conjunctival papilloma, recurrences are not uncommon, ranging from 3% to 27%.[78] Huang et al. investigated the clinical features, treatment, and factors related to the recurrence of conjunctival papilloma. Their results suggest that surgical excision with adequate adjunctive therapy such as double freeze–thaw cryotherapy, intraoperative mitomycin-C, and/or carbon dioxide laser-assisted resection can reduce the risk of recurrence rate of conjunctival papilloma.

Treatment of Primary Acquired Nasolacrimal Duct Obstruction: Endoscopic or External Dacryocystorhinostomy?

Transcutaneous or external dacryocystorhinostomy has long been the standard procedure for treating primary acquired nasolacrimal duct obstruction. However, endoscopic endonasal dacryocystorhinostomy has become an increasingly popular procedure for this disease with the advent of new endoscopy instruments and technique.[9] In this issue, Su and Chang compared the success rates of endoscopic endonasal dacryocystorhinostomy and external dacryocystorhinostomy for the treatment of acquired nasolacrimal duct obstruction. Their results reveal that there was no statistically significant difference between endoscopic and external approaches. They suggest that endoscopic dacryocystorhinostomy can provide higher satisfaction due to quicker recovery and no external incision and should be considered as the primary treatment choice for acquired nasolacrimal duct obstruction.
  9 in total

1.  Epibulbar tumors.

Authors:  J E ASH
Journal:  Am J Ophthalmol       Date:  1950-08       Impact factor: 5.258

Review 2.  IgG4-related disease: a complex under-diagnosed clinical entity.

Authors:  Sujani Yadlapati; Elijah Verheyen; Petros Efthimiou
Journal:  Rheumatol Int       Date:  2017-07-05       Impact factor: 2.631

3.  Endonasal dacryocystorhinostomy: a modified technique with preservation of the nasal and lacrimal mucosa.

Authors:  François Codère; Paul Denton; Jorge Corona
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2010 May-Jun       Impact factor: 1.746

4.  Aetiology and surgical treatment of childhood blepharoptosis.

Authors:  V Lee; H Konrad; C Bunce; C Nelson; J R O Collin
Journal:  Br J Ophthalmol       Date:  2002-11       Impact factor: 4.638

5.  Ocular adnexal IgG4-related disease: clinical features, outcome, and factors associated with response to systemic steroids.

Authors:  Wei-Kuang Yu; Shu-Ching Kao; Ching-Fen Yang; Fenq-Lih Lee; Chieh-Chih Tsai
Journal:  Jpn J Ophthalmol       Date:  2014-11-07       Impact factor: 2.447

6.  Conjunctival papilloma: features and outcomes based on age at initial examination.

Authors:  Swathi Kaliki; Sruthi Arepalli; Carol L Shields; Kendra Klein; Hong Sun; Eralda Hysenj; Sara E Lally; Jerry A Shields
Journal:  JAMA Ophthalmol       Date:  2013-05       Impact factor: 7.389

7.  A prevalence study of IgG4-related ophthalmic disease in Japan.

Authors: 
Journal:  Jpn J Ophthalmol       Date:  2013-08-07       Impact factor: 2.447

8.  Paediatric blepharoptosis: a 10-year review.

Authors:  A Berry-Brincat; H Willshaw
Journal:  Eye (Lond)       Date:  2008-10-24       Impact factor: 3.775

9.  Amblyopia in ptosis.

Authors:  R L Anderson; S A Baumgartner
Journal:  Arch Ophthalmol       Date:  1980-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.